ATE205713T1 - Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit - Google Patents

Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit

Info

Publication number
ATE205713T1
ATE205713T1 AT94200484T AT94200484T ATE205713T1 AT E205713 T1 ATE205713 T1 AT E205713T1 AT 94200484 T AT94200484 T AT 94200484T AT 94200484 T AT94200484 T AT 94200484T AT E205713 T1 ATE205713 T1 AT E205713T1
Authority
AT
Austria
Prior art keywords
agent
mast cell
drug delivery
transdermal drug
sensitizing
Prior art date
Application number
AT94200484T
Other languages
English (en)
Inventor
John Wille
Agis Kydonieus
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE205713(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE205713T1 publication Critical patent/ATE205713T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94200484T 1993-02-25 1994-02-25 Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit ATE205713T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2208093A 1993-02-25 1993-02-25

Publications (1)

Publication Number Publication Date
ATE205713T1 true ATE205713T1 (de) 2001-10-15

Family

ID=21807714

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94200484T ATE205713T1 (de) 1993-02-25 1994-02-25 Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit

Country Status (8)

Country Link
EP (1) EP0612525B1 (de)
JP (1) JPH072670A (de)
AT (1) ATE205713T1 (de)
AU (1) AU686123B2 (de)
CA (1) CA2114968A1 (de)
DE (1) DE69428295T2 (de)
MX (1) MX9401331A (de)
ZA (1) ZA94856B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
FR2719474B1 (fr) 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US5672640A (en) * 1995-07-12 1997-09-30 Caschem, Inc. Polypropylene compatible grease compositions for optical fiber cable
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
CA2200984A1 (en) * 1995-07-25 1997-02-13 Samir S. Mitragotri Enhanced transdermal transfer using ultrasound
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
FR2740040B1 (fr) * 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
AU3309097A (en) * 1996-06-12 1998-01-07 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
JP2002515786A (ja) 1996-06-28 2002-05-28 ソントラ メディカル，エル．ピー． 経皮輸送の超音波増強
US7066884B2 (en) 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US7812010B2 (en) * 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus
US7943166B2 (en) * 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
FI20031793A0 (fi) * 2003-12-09 2003-12-09 Lasse Leino Uusi anti-proliferatiivinen farmaseuttinen koostumus
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060094944A1 (en) 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis with error correction
US8372040B2 (en) 2005-05-24 2013-02-12 Chrono Therapeutics, Inc. Portable drug delivery device including a detachable and replaceable administration or dosing element
ES2553179T3 (es) * 2005-08-01 2015-12-04 Maruho Co., Ltd. Preparación de una loción que contiene un derivado del ácido piridoncarboxílico
US7432069B2 (en) 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
KR101433550B1 (ko) 2007-03-07 2014-08-27 에코 테라퓨틱스, 인크. 경피 피분석물 모니터링 시스템 및 피분석물 검출 방법
NZ580997A (en) 2007-04-27 2011-08-26 Echo Therapeutics Inc Dermal abrasion device with feedback electrode to deliver data on skin thickness and removable abrasion heads
JP5758587B2 (ja) * 2010-05-13 2015-08-05 智 堀越 ビニルイミダゾール類の光異性化方法
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
ES2075272T5 (es) * 1990-06-29 2002-07-01 Gs Dev Ab Composiciones dermatologicas conteniendo acido cis-urocanico.
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices

Also Published As

Publication number Publication date
JPH072670A (ja) 1995-01-06
DE69428295T2 (de) 2002-06-20
AU686123B2 (en) 1998-02-05
EP0612525B1 (de) 2001-09-19
AU5635094A (en) 1994-09-01
ZA94856B (en) 1994-09-05
DE69428295D1 (de) 2001-10-25
EP0612525A1 (de) 1994-08-31
CA2114968A1 (en) 1994-08-26
MX9401331A (es) 1994-08-31

Similar Documents

Publication Publication Date Title
AU686123B2 (en) Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
EP0336880A3 (de) Verwendung von topisch applizierbaren Präparaten zur Behandlung der Altershaut
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
EP0172228A4 (de) Substrat zum verabreichen aktiver arzneimittel auf menschliche haut.
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
ATE66139T1 (de) Kosmetische zusammensetzung.
SE8403487D0 (sv) Farmaceutisk komposition
ES479474A1 (es) Procedimiento para la obtencion de una composicion a base dederivados de la piridina de accion cerebral.
ATE63220T1 (de) Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben.
DK0610595T3 (da) Sammensætning af L-DOPA-estere
KR950703972A (ko) 항혈전성 치료 및 암 예방을 위한 아세틸살리실산을 함유하는 경피 투여 시스템(transdermal administration system containing acetylsalicyliic acid for antithrombotic therapy and the prevention of cancer)
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
SE8001599L (sv) Transdermalt medicineringssystem for isosorbiddinitrat
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATA21888A (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
ATE135909T1 (de) Verfahren zur behandlung von akne
DE69325236D1 (de) Pharmazeutische Zusammensetzungen enthaltend Urodeoxycholicsäure
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
US3510554A (en) Composition and method for hardening finger- and toenails
JPS635378B2 (de)
DE69021405D1 (de) System zur gesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu dessen Herstellung.
JPH07557B2 (ja) 皮膚炎に対する治療用組成物
US20160184331A1 (en) Base and external preparation for skin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties